An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
ENDRA Life Sciences to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
ENDRA Life Sciences Inc. (NASDAQ: NDRA) will present a company overview at the H.C. Wainwright 6th Annual NASH Investor Conference on October 17, 2022, in a virtual format, alongside one-on-one meetings. ENDRA has developed the Thermo Acoustic Enhanced UltraSound (TAEUS®) technology, a cost-effective imaging solution aimed at diagnosing liver conditions affecting over one billion people globally. TAEUS® is designed to work with existing ultrasound systems and focuses on non-invasive liver fat measurement, relevant for Non-Alcoholic Fatty Liver Disease (NAFLD) and NASH.
Positive
None.
Negative
None.
ANN ARBOR, Mich.--(BUSINESS WIRE)--
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that management will present a company overview at the H.C. Wainwright 6th Annual NASH Investor Conference being held October 17, 2022 in a virtual format, and will also be holding one-on-one virtual meetings. To request a meeting, please contact H.C. Wainwright or Yvonne Briggs of LHA at ybriggs@lhai.com.
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care. TAEUS® is designed to work in concert with over 500,000 ultrasound systems in use globally today. TAEUS® is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS®, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.
What is the purpose of ENDRA Life Sciences' presentation at the H.C. Wainwright NASH Investor Conference?
ENDRA Life Sciences Inc. will provide a company overview and discuss its innovative TAEUS® technology aimed at liver condition diagnostics.
When will ENDRA Life Sciences present at the NASH Investor Conference?
ENDRA Life Sciences Inc. will present on October 17, 2022.
What technology does ENDRA Life Sciences focus on for liver disease diagnostics?
ENDRA Life Sciences focuses on Thermo Acoustic Enhanced UltraSound (TAEUS®) technology for diagnosing liver conditions.
How does TAEUS® technology benefit liver disease diagnosis?
TAEUS® allows for visualization of liver fat at a significantly lower cost compared to traditional imaging methods, making it accessible at the point of care.
What conditions does TAEUS® address?
TAEUS® is focused on measuring fat in the liver for assessing Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH).
